2024-10-24 22:47:38,797 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Very Low" before October 1, 2024?
2024-10-24 22:47:38,798 - INFO - Run 0:
**INT. NEWS STUDIO - DAY AFTER EVENT**

*NATE SILVER and PHILIP TETLOCK sit across from each other, papers in hand.*

**NATE SILVER**  
So, Philip, the big question: Did the CDC's risk assessment for mpox exceed "Very Low"?

**PHILIP TETLOCK**  
No, our models had it at 12.75%. The likelihood of a shift was minimal, given the data up to August 23.

**NATE SILVER**  
Right, with the clade I situation in Africa, there was concern, but the U.S. population's immunity levels and containment measures held strong.

**PHILIP TETLOCK**  
Exactly. The CDC's ongoing updates were crucial, but the risk remained contained. Our models factored in all variables—travel, exposure, immunity.

**NATE SILVER**  
And once again, the accuracy of our forecasting models is confirmed.

*They exchange a knowing nod, confident in their analysis.*

**PHILIP TETLOCK**  
Until the next challenge, Nate.

**NATE SILVER**  
Absolutely, Philip.

2024-10-24 22:47:42,892 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Very Low" before October 1, 2024?
2024-10-24 22:47:42,892 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Very Low" before October 1, 2024?
2024-10-24 22:47:42,892 - INFO - Run 1:
**INT. NEWSROOM - DAY AFTER EVENT - SEPTEMBER 13, 2024**

*The newsroom is bustling. NATE SILVER and PHILIP TETLOCK sit at a table, papers spread before them.*

**NATE SILVER**  
So, about the CDC's mpox risk assessment... did it exceed "Very Low"?

**PHILIP TETLOCK**  
No, our models had it at 12.34%. The indicators just weren't there.

**NATE SILVER**  
Right. The data up to August 23rd showed stability. Even with clade I concerns, the overall immunity levels held strong.

**PHILIP TETLOCK**  
And the CDC's updates were thorough. They didn't see a shift in risk either.

**NATE SILVER**  
It's fascinating how our models align with reality. The public's response remains calm, with no major disruptions.

**PHILIP TETLOCK**  
Indeed. We'll keep monitoring, but for now, it seems the risk remains very low.

*They exchange a knowing glance, confident in their predictive prowess.*

2024-10-24 22:47:42,892 - INFO - Run 1:
**INT. NEWSROOM - DAY AFTER EVENT - SEPTEMBER 13, 2024**

*The newsroom is bustling. NATE SILVER and PHILIP TETLOCK sit at a table, papers spread before them.*

**NATE SILVER**  
So, about the CDC's mpox risk assessment... did it exceed "Very Low"?

**PHILIP TETLOCK**  
No, our models had it at 12.34%. The indicators just weren't there.

**NATE SILVER**  
Right. The data up to August 23rd showed stability. Even with clade I concerns, the overall immunity levels held strong.

**PHILIP TETLOCK**  
And the CDC's updates were thorough. They didn't see a shift in risk either.

**NATE SILVER**  
It's fascinating how our models align with reality. The public's response remains calm, with no major disruptions.

**PHILIP TETLOCK**  
Indeed. We'll keep monitoring, but for now, it seems the risk remains very low.

*They exchange a knowing glance, confident in their predictive prowess.*

2024-10-24 22:47:46,980 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Very Low" before October 1, 2024?
2024-10-24 22:47:46,980 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Very Low" before October 1, 2024?
2024-10-24 22:47:46,980 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Very Low" before October 1, 2024?
2024-10-24 22:47:46,980 - INFO - Run 2:
**INT. NEWS STUDIO - DAY**

*Nate Silver and Philip Tetlock sit across from each other, papers scattered around them.*

**NATE SILVER:** So, the big question: Did the CDC's risk assessment for mpox exceed "Very Low"?

**PHILIP TETLOCK:** No, our models had it at 15.67%. Despite the clade I spread in Sub-Saharan Africa, the U.S. population's immunity and effective treatments kept the risk low.

**NATE SILVER:** Interesting. The models accounted for the CDC's July update and the ongoing monitoring. Still, the probability stayed firmly below the threshold.

**PHILIP TETLOCK:** Exactly. The CDC's qualitative judgements and our data aligned. No major shifts in infection likelihood or impact on the general population.

**NATE SILVER:** Another testament to the accuracy of our forecasting models. Until next time, let's keep an eye on these evolving risks.

*They nod, satisfied with their analysis, as the studio lights dim.*

2024-10-24 22:47:46,980 - INFO - Run 2:
**INT. NEWS STUDIO - DAY**

*Nate Silver and Philip Tetlock sit across from each other, papers scattered around them.*

**NATE SILVER:** So, the big question: Did the CDC's risk assessment for mpox exceed "Very Low"?

**PHILIP TETLOCK:** No, our models had it at 15.67%. Despite the clade I spread in Sub-Saharan Africa, the U.S. population's immunity and effective treatments kept the risk low.

**NATE SILVER:** Interesting. The models accounted for the CDC's July update and the ongoing monitoring. Still, the probability stayed firmly below the threshold.

**PHILIP TETLOCK:** Exactly. The CDC's qualitative judgements and our data aligned. No major shifts in infection likelihood or impact on the general population.

**NATE SILVER:** Another testament to the accuracy of our forecasting models. Until next time, let's keep an eye on these evolving risks.

*They nod, satisfied with their analysis, as the studio lights dim.*

2024-10-24 22:47:46,980 - INFO - Run 2:
**INT. NEWS STUDIO - DAY**

*Nate Silver and Philip Tetlock sit across from each other, papers scattered around them.*

**NATE SILVER:** So, the big question: Did the CDC's risk assessment for mpox exceed "Very Low"?

**PHILIP TETLOCK:** No, our models had it at 15.67%. Despite the clade I spread in Sub-Saharan Africa, the U.S. population's immunity and effective treatments kept the risk low.

**NATE SILVER:** Interesting. The models accounted for the CDC's July update and the ongoing monitoring. Still, the probability stayed firmly below the threshold.

**PHILIP TETLOCK:** Exactly. The CDC's qualitative judgements and our data aligned. No major shifts in infection likelihood or impact on the general population.

**NATE SILVER:** Another testament to the accuracy of our forecasting models. Until next time, let's keep an eye on these evolving risks.

*They nod, satisfied with their analysis, as the studio lights dim.*

2024-10-24 22:47:50,672 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Very Low" before October 1, 2024?
2024-10-24 22:47:50,672 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Very Low" before October 1, 2024?
2024-10-24 22:47:50,672 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Very Low" before October 1, 2024?
2024-10-24 22:47:50,672 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Very Low" before October 1, 2024?
2024-10-24 22:47:50,672 - INFO - Run 3:
**INT. NEWSROOM - DAY AFTER EVENT - SEPTEMBER 13, 2024**

*NATE SILVER and PHILIP TETLOCK sit across from each other, papers spread out between them.*

**NATE SILVER**  
Well, Philip, here we are. The CDC's latest assessment came in yesterday, and it’s still marked as "Very Low."

**PHILIP TETLOCK**  
Indeed, Nate. Our models had it at 12.34% for the risk to exceed "Very Low" before October. The data up to August 23rd didn't indicate a significant shift.

**NATE SILVER**  
Right. The situation in Sub-Saharan Africa was concerning, but the transmission dynamics here just didn't support a higher risk level.

**PHILIP TETLOCK**  
Exactly. The pathogen's infectiousness and the population's immunity levels kept the probabilities low. 

**NATE SILVER**  
So, no surprises this time. The models hold strong.

**PHILIP TETLOCK**  
Yes, no surprises. Our models were accurate as always.

2024-10-24 22:47:50,672 - INFO - Run 3:
**INT. NEWSROOM - DAY AFTER EVENT - SEPTEMBER 13, 2024**

*NATE SILVER and PHILIP TETLOCK sit across from each other, papers spread out between them.*

**NATE SILVER**  
Well, Philip, here we are. The CDC's latest assessment came in yesterday, and it’s still marked as "Very Low."

**PHILIP TETLOCK**  
Indeed, Nate. Our models had it at 12.34% for the risk to exceed "Very Low" before October. The data up to August 23rd didn't indicate a significant shift.

**NATE SILVER**  
Right. The situation in Sub-Saharan Africa was concerning, but the transmission dynamics here just didn't support a higher risk level.

**PHILIP TETLOCK**  
Exactly. The pathogen's infectiousness and the population's immunity levels kept the probabilities low. 

**NATE SILVER**  
So, no surprises this time. The models hold strong.

**PHILIP TETLOCK**  
Yes, no surprises. Our models were accurate as always.

2024-10-24 22:47:50,672 - INFO - Run 3:
**INT. NEWSROOM - DAY AFTER EVENT - SEPTEMBER 13, 2024**

*NATE SILVER and PHILIP TETLOCK sit across from each other, papers spread out between them.*

**NATE SILVER**  
Well, Philip, here we are. The CDC's latest assessment came in yesterday, and it’s still marked as "Very Low."

**PHILIP TETLOCK**  
Indeed, Nate. Our models had it at 12.34% for the risk to exceed "Very Low" before October. The data up to August 23rd didn't indicate a significant shift.

**NATE SILVER**  
Right. The situation in Sub-Saharan Africa was concerning, but the transmission dynamics here just didn't support a higher risk level.

**PHILIP TETLOCK**  
Exactly. The pathogen's infectiousness and the population's immunity levels kept the probabilities low. 

**NATE SILVER**  
So, no surprises this time. The models hold strong.

**PHILIP TETLOCK**  
Yes, no surprises. Our models were accurate as always.

2024-10-24 22:47:50,672 - INFO - Run 3:
**INT. NEWSROOM - DAY AFTER EVENT - SEPTEMBER 13, 2024**

*NATE SILVER and PHILIP TETLOCK sit across from each other, papers spread out between them.*

**NATE SILVER**  
Well, Philip, here we are. The CDC's latest assessment came in yesterday, and it’s still marked as "Very Low."

**PHILIP TETLOCK**  
Indeed, Nate. Our models had it at 12.34% for the risk to exceed "Very Low" before October. The data up to August 23rd didn't indicate a significant shift.

**NATE SILVER**  
Right. The situation in Sub-Saharan Africa was concerning, but the transmission dynamics here just didn't support a higher risk level.

**PHILIP TETLOCK**  
Exactly. The pathogen's infectiousness and the population's immunity levels kept the probabilities low. 

**NATE SILVER**  
So, no surprises this time. The models hold strong.

**PHILIP TETLOCK**  
Yes, no surprises. Our models were accurate as always.

2024-10-24 22:47:55,294 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Very Low" before October 1, 2024?
2024-10-24 22:47:55,294 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Very Low" before October 1, 2024?
2024-10-24 22:47:55,294 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Very Low" before October 1, 2024?
2024-10-24 22:47:55,294 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Very Low" before October 1, 2024?
2024-10-24 22:47:55,294 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "Very Low" before October 1, 2024?
2024-10-24 22:47:55,294 - INFO - Run 4:
**INT. NEWS STUDIO - DAY**

*NATE SILVER and PHILIP TETLOCK sit across from each other, papers in hand.*

**NATE SILVER**  
Well, Philip, the CDC's latest assessment is out. Will the risk of mpox exceed "Very Low" before October 1, 2024?

**PHILIP TETLOCK**  
No, Nate. Our models had it at 12.34%. The situation in Sub-Saharan Africa raised concerns, but the transmission dynamics here remain stable.

**NATE SILVER**  
Indeed. The CDC's rapid response and public health measures have kept the risk contained. It's a testament to their preparedness.

**PHILIP TETLOCK**  
Absolutely. The public's immunity levels and effective treatments have played significant roles in maintaining this status.

*NATE nods, flipping through his notes.*

**NATE SILVER**  
It's reassuring to see the models align with reality. Let's hope it stays that way.

*They exchange a knowing glance, the weight of accurate predictions evident.*

**FADE OUT.**

2024-10-24 22:47:55,294 - INFO - Run 4:
**INT. NEWS STUDIO - DAY**

*NATE SILVER and PHILIP TETLOCK sit across from each other, papers in hand.*

**NATE SILVER**  
Well, Philip, the CDC's latest assessment is out. Will the risk of mpox exceed "Very Low" before October 1, 2024?

**PHILIP TETLOCK**  
No, Nate. Our models had it at 12.34%. The situation in Sub-Saharan Africa raised concerns, but the transmission dynamics here remain stable.

**NATE SILVER**  
Indeed. The CDC's rapid response and public health measures have kept the risk contained. It's a testament to their preparedness.

**PHILIP TETLOCK**  
Absolutely. The public's immunity levels and effective treatments have played significant roles in maintaining this status.

*NATE nods, flipping through his notes.*

**NATE SILVER**  
It's reassuring to see the models align with reality. Let's hope it stays that way.

*They exchange a knowing glance, the weight of accurate predictions evident.*

**FADE OUT.**

2024-10-24 22:47:55,294 - INFO - Run 4:
**INT. NEWS STUDIO - DAY**

*NATE SILVER and PHILIP TETLOCK sit across from each other, papers in hand.*

**NATE SILVER**  
Well, Philip, the CDC's latest assessment is out. Will the risk of mpox exceed "Very Low" before October 1, 2024?

**PHILIP TETLOCK**  
No, Nate. Our models had it at 12.34%. The situation in Sub-Saharan Africa raised concerns, but the transmission dynamics here remain stable.

**NATE SILVER**  
Indeed. The CDC's rapid response and public health measures have kept the risk contained. It's a testament to their preparedness.

**PHILIP TETLOCK**  
Absolutely. The public's immunity levels and effective treatments have played significant roles in maintaining this status.

*NATE nods, flipping through his notes.*

**NATE SILVER**  
It's reassuring to see the models align with reality. Let's hope it stays that way.

*They exchange a knowing glance, the weight of accurate predictions evident.*

**FADE OUT.**

2024-10-24 22:47:55,294 - INFO - Run 4:
**INT. NEWS STUDIO - DAY**

*NATE SILVER and PHILIP TETLOCK sit across from each other, papers in hand.*

**NATE SILVER**  
Well, Philip, the CDC's latest assessment is out. Will the risk of mpox exceed "Very Low" before October 1, 2024?

**PHILIP TETLOCK**  
No, Nate. Our models had it at 12.34%. The situation in Sub-Saharan Africa raised concerns, but the transmission dynamics here remain stable.

**NATE SILVER**  
Indeed. The CDC's rapid response and public health measures have kept the risk contained. It's a testament to their preparedness.

**PHILIP TETLOCK**  
Absolutely. The public's immunity levels and effective treatments have played significant roles in maintaining this status.

*NATE nods, flipping through his notes.*

**NATE SILVER**  
It's reassuring to see the models align with reality. Let's hope it stays that way.

*They exchange a knowing glance, the weight of accurate predictions evident.*

**FADE OUT.**

2024-10-24 22:47:55,294 - INFO - Run 4:
**INT. NEWS STUDIO - DAY**

*NATE SILVER and PHILIP TETLOCK sit across from each other, papers in hand.*

**NATE SILVER**  
Well, Philip, the CDC's latest assessment is out. Will the risk of mpox exceed "Very Low" before October 1, 2024?

**PHILIP TETLOCK**  
No, Nate. Our models had it at 12.34%. The situation in Sub-Saharan Africa raised concerns, but the transmission dynamics here remain stable.

**NATE SILVER**  
Indeed. The CDC's rapid response and public health measures have kept the risk contained. It's a testament to their preparedness.

**PHILIP TETLOCK**  
Absolutely. The public's immunity levels and effective treatments have played significant roles in maintaining this status.

*NATE nods, flipping through his notes.*

**NATE SILVER**  
It's reassuring to see the models align with reality. Let's hope it stays that way.

*They exchange a knowing glance, the weight of accurate predictions evident.*

**FADE OUT.**

